Published in Pharma Law Weekly, January 23rd, 2007
This trend article about University of Rome, Italy, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: A new study, "Sensitization of human colon adenocarcinoma cells (LoVo) to reactive oxygen species by a lysosomotropic compound," is now available. According to recent research from Rome, Italy, "The in situ formation of cytotoxic metabolites by an enzyme-catalyzed reaction is a recent approach in cancer therapy. The present results show that multidrug-resistant human colon adenocarcinoma cells (LoVo) are significantly more sensitive than corresponding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.